Friday, June 12, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 171 of 1,261
  1. US 11752130

    Carboxylated psilocybin derivatives and methods of using

    Enveric Biosciences Canada Inc. Β· Granted Sep 12, 2023 Β· Expires Sep 7, 2043

    granted
  2. US 11752137

    Ophthalmic compositions for treating ocular Demodex using lotilaner formulations

    Tarsus Pharmaceuticals, Inc. Β· Granted Sep 12, 2023 Β· Expires Sep 7, 2043

    granted
  3. US 11752223

    Method for producing Ac-225 solution and method for producing medicine using Ac-225 solution

    NATIONAL INSTITUTES FOR QUANTUM SCIENCE AND TECHNOLOGY Β· Granted Sep 12, 2023 Β· Expires Sep 7, 2043

    granted
  4. US 11752184

    Bioactive concentrates and uses thereof

    PURPLE MUNDO, INC. Β· Granted Sep 12, 2023 Β· Expires Sep 7, 2043

    granted
  5. US 11753408

    Compounds and method for blocking transmission of malarial parasite

    The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Sep 12, 2023 Β· Expires Sep 7, 2043

    granted
  6. US 11753628

    HSD17B13 variants and uses thereof

    REGENERON PHARMACEUTICALS, INC. Β· Granted Sep 12, 2023 Β· Expires Sep 7, 2043

    granted
  7. US 11753630

    Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin gene

    Precision BioSciences, Inc. Β· Granted Sep 12, 2023 Β· Expires Sep 7, 2043

    granted
  8. US 11753366

    Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors

    NIKANG THERAPEUTICS, INC. Β· Granted Sep 12, 2023 Β· Expires Sep 7, 2043

    granted
  9. US 11753627

    Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3β€²-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4

    The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Sep 12, 2023 Β· Expires Sep 7, 2043

    granted
  10. US 11753369

    Creatine prodrugs, compositions and methods of use thereof

    Ultragenyx Pharmaceutical Inc. Β· Granted Sep 12, 2023 Β· Expires Sep 7, 2043

    granted
  11. US 11753377

    Crystal form of 2-methyl-2-propanol and amino-substituted aryl compound

    ZHUHAI UNITED LABORATORIES CO., LTD. Β· Granted Sep 12, 2023 Β· Expires Sep 7, 2043

    granted
  12. US 11753466

    Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof

    CytomX Therapeutics, Inc. Β· Granted Sep 12, 2023 Β· Expires Sep 7, 2043

    granted
  13. US 11753381

    Inhibitors of receptor interacting protein kinase I for the treatment of disease

    The Board of Regents of the University of Texas System Β· Granted Sep 12, 2023 Β· Expires Sep 7, 2043

    granted
  14. US 11753459

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. Β· Granted Sep 12, 2023 Β· Expires Sep 7, 2043

    granted
  15. US 11753447

    Cyclic peptides, methods of synthesis, and methods of treatment

    The Regents of the University of California Β· Granted Sep 12, 2023 Β· Expires Sep 7, 2043

    granted
  16. US 11753644

    Compounds and methods for reducing IFNAR1 expression

    Ionis Pharmaceuticals, Inc. Β· Granted Sep 12, 2023 Β· Expires Sep 7, 2043

    granted
  17. US 11753461

    Optimized factor VIII genes

    BIOVERATIV THERAPEUTICS INC. Β· Granted Sep 12, 2023 Β· Expires Sep 7, 2043

    granted
  18. US 11753474

    Anti-Dectin-2 antibodies

    Bolt Biotherapeutics, Inc. Β· Granted Sep 12, 2023 Β· Expires Sep 7, 2043

    granted
  19. US 11753443

    Conjugated hepcidin mimetics

    Protagonist Therapeutics, Inc. Β· Granted Sep 12, 2023 Β· Expires Sep 7, 2043

    granted
  20. US 11753397

    Cereblon binders for the degradation of ikaros

    C4 THERAPEUTICS, INC. Β· Granted Sep 12, 2023 Β· Expires Sep 7, 2043

    granted
  21. US 11753623

    Compositions for treating retinal diseases and methods for making and using them

    The Regents of the University of California Β· Granted Sep 12, 2023 Β· Expires Sep 7, 2043

    granted
  22. US 11753398

    Therapeutic compounds

    C4X Discovery Limited Β· Granted Sep 12, 2023 Β· Expires Sep 7, 2043

    granted
  23. CA 3245150

    COMBINAISONS AVEC UN ANTICORPS ANTI-CD39 HUMAIN, UN ANTICORPS ANTI-PD-1 HUMAIN ET UNE CHIMIOTHÉRAPIE CONTRE LE CANCER GASTRIQUE

    TRISHULA THERAPEUTICS INC [US] Β· Granted Sep 7, 2023 Β· Expires Sep 2, 2043

    granted
  24. US 11746124

    Chemoselective thiol-conjugation with alkene or alkyne-phosphonamidates

    Ludwig-Maximilians-Universitat Munchen Β· Granted Sep 5, 2023 Β· Expires Aug 31, 2043

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.